Equine pituitary pars intermedia dysfunction (PPID) can be detected earlier and more reliably with a new set of guidelines developed by the Equine Endocrinology Group (EEG), a body of leading veterinarians and researchers in the field of equine endocrinology.
Showing posts with label endocrine. Show all posts
Showing posts with label endocrine. Show all posts
Wednesday, December 04, 2013
PPID: Equine endocrinology researchers revise guidelines for "Cushings" tests for horses
Equine pituitary pars intermedia dysfunction (PPID) can be detected earlier and more reliably with a new set of guidelines developed by the Equine Endocrinology Group (EEG), a body of leading veterinarians and researchers in the field of equine endocrinology.
Wednesday, September 19, 2012
Paynter Watch: How Is Post-Colitis Laminitis Different from Common Chronic Laminitis?
TVG interview with champion Thoroughbred Paynter's owner Ahmed Zayat of Zayat Racing, taped the morning of September 19, 2012, explains the timeline of Paynter's illness and suggests the severity of the colt's illness.
Second, that damage causes horses great pain. The common analogy of standing and bearing weight on a ripped toenail is an apt one.
But the most common types of laminitis are rooted in the horse’s endocrine (hormone-producing) system.
Hormonal imbalances are aggravated by environment, diet, exercise and seasons. Damage to the laminar junction may be slow but steady, with varying intensity.
With this type, horse owners are stunned when told their horses have laminitis...and that they have had it for months or even years. It just didn’t cause enough pain for the horse to be noticeably lame.
The farrier may have noticed a stretched white line or hoof wall ridges, or that a normally-quiet horse is irritable while being shod. The rider might have thought the horse wasn’t as free-striding as he once was.
A horse that once was hard to catch is suddenly an easy catch. But the owners don't sense that these horses are lame--until they are. Then the subtle signs and the loss of performance start to make sense.
How can this be?
The progressive stages of programmed cell death, or apoptosis, in a human cancer cell. (Image courtesy of Wellcome Images library) |
Cellular death in endocrine-related laminitis is by the process known as apoptosis. Cells in the lamininar zone are under assault. Some may contract and die. Some may stretch and deform. Some may be unaffected and remain attached. One by one, the cells die.
The horse is more lame one day, less lame the next. The blood supply may be disrupted and the diseased hoof grows abnormally and loses its form. As the seasons change, the horse is better, or worse. Low-grade chronic laminitis can go on and on for months or years.
Another form of cell death is seen in the horse that has received a severe insult to its body’s system from the inflammation, shock and dehydration of colitis. Instead of the drip-by-drip influx of insulting factors into the foot, a flood arrives and the result is the traumatic cell die-off process known as necrosis.
Apoptosis and necrosis are flip sides of the coin of cellular death. Both are associated with the process known as laminitis, but one is a systematic death of cells, while the other is swift and deadly and immediate. One text described apoptosis as cellular suicide, and necrosis as cellular homicide.
The recent case of top three-year-old colt Paynter has been captivating the racing world. Paynter has been in a veterinary hospital in upstate New York near Saratoga since Labor Day weekend. His condition has improved but his owner reports persistent fever and diarrhea bouts, and the colt was diagnosed with laminitis in three of his four feet.
Equine podiatry specialist Dr. Bryan Fraley from Lexington, Kentucky went to New York to work on the horse; his feet are now in casts, which have been reported to be successful. Reports after the first week were that there was no rotation or sinking in the feet. The casts are due to be changed later this week.
Many of us have been there...and done that, when it comes to watching a horse struggle with the severe colitis and resulting dehydration of colitis. Too many of us have lost horses swiftly and tragically in the days following a successful survival--not to colitis, but to the severe laminitis that so often follows.
What is colitis?
Colitis: inflammation of the colon, usually due to infection. Diarrhea, colic pain and rapidly progressing dehydration are usually the result. Treatment focuses on relieving symptoms and preventing dehydration and shock while identifying and treating the underlying cause, if possible. (Definition: American Association of Equine Practitioners)To understand colitis-related laminitis better, we turned to David Hood DVM, PhD of The Hoof Diagnostic and Rehabilitation Clinic, a laminitis research and treatment center outside College Station, Texas.
Dr David Hood during a panel discussion at the Sixth International Equine Conference on Laminitis and Diseases of the Foot in 2011. (Dick Booth photo) |
One of the world's most highly respected laminitis researchers, Dr. Hood’s focus is on understanding the process of laminitis and, in particular, how the foot tissue is damaged by the disease.
Dr. Hood explained that the difference between apoptosis and necrosis is central to understanding why a horse has such a sudden and devastating form of laminitis after colitis--and why the laminitis doesn’t occur until the diarrhea has stopped.
Dr. Hood mentioned that the chief culprit in colitis is that the horse goes into shock. In response to the inflammation in the bowel caused by colitis, the horse’s system demands that a large volume of fluid be pulled out of cells all over the body. It is pumped to the bowel to replace the fluid lost there but, as a result, the circulatory system is left with a deficit of fluid.
When treated by a veterinarian, the sick horse will receive lifesaving intravenous fluids. The circulation is refueled or rehydrated. But that is the cue for laminitis to begin.
This plastination specimen illustrates chronic laminitis and typical hoof capsule deformity. |
It is in the reperfusion stage that necrosis in the foot tissue takes place. This is why the onset of laminitis seems to follow the diarhhea in the medical timeline of the disease.
Not only is laminitis by necrosis sudden and traumatic, the cellular death in the laminar zone causes a collapse of the foot’s ability to support the weakened horse, and severe pain is obvious and extreme.
“By the time you see that it has happened, there’s not much to do except start rehabiliation,” Dr. Hood commented. “It’s like a patient who just had a heart attack: the damage is done, and the patient’s prognosis depends on how much damage was done.”
Dr. Hood noted that post-colitis laminitis is also very different from the third form of laminitis, known as "support-limb" laminitis. “That’s also a slow onset,” he remarked. “And the cellular death is not necessarily necrosis. The foot is almost anesthetized while the horse is standing continually on it. It’s not until the blood flow comes back that the horse begins to show signs of pain.”
Do post-colitis cases tend to demonstrate sinker syndrome rather than the rotation type of coffin bone detachment seen in typical laminitis? “It all depends,” Dr. Hood said, “on the amount of damage and the percent of lamina that have experienced acute necrosis.”
Endotoxin has been implicated as a factor in post-colitis lamintiis but Dr. Hood discounted it. “Research data indicate that while endotoxin can make a horse sick and can cause shock,” he stressed. “it--alone--does not induce laminitis.”
Are there facts that are known about colitis in horses? Dr. Hood agreed that much is known about post-colitis laminitis and fired off a quick list: horses do survive it. It’s a painful condition. It’s hard to control. Horses undergo rapid and radical damage to their feet. There are different varieties. Rehabilitation of damaged hooves after colitis can take months or even years. The more the foot is damaged, the harder it is to fully rehabilitate the foot.
In endocrine-related laminitis, on the other hand, Dr. Hood said the situation is reversed. The feet are relatively easy to treat. It’s the disease condition that is difficult.
Laminitis, in any of its forms, is a medical emergency and a critical juncture in a horse's medical history and athletic potential.
We all hope that Paynter will continue to successfully fight both colitis and laminitis.
Thanks to Dr. Hood for his time and expertise in sharing and preparing information for this article. Plastination specimen courtesy of Christoph von Horst, DVM PhD.
To learn more:
Dr. David Hood Launches the Hoof Diagnostic and Rehabilitation Clinic in Texas
Paynter Watch: Top Thoroughbred Colt Diagnosed with Post-Colitis Laminitis in New York
Paynter Laminitis Watch: Podiatry-Vet Fraley Amazed at Progress Since Hoof Casts Applied
© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is a between-issues news service for subscribers to Hoofcare and Lameness Journal. Please, no use without permission. You only need to ask. This blog may be read online at the blog page, checked via RSS feed, or received via a digest-type email (requires signup in box at top right of blog page). To subscribe to Hoofcare and Lameness (the journal), please visit the main site, www.hoofcare.com, where many educational products and media related to equine lameness and hoof science can be found. Questions or problems with this blog? Send email to blog@hoofcare.com.
Follow Hoofcare + Lameness on Twitter: @HoofcareJournal
Read this blog's headlines on the Hoofcare + Lameness Facebook Page
Disclosure of Material Connection: I have not received any direct compensation for writing this post. I have no material connection to the brands, products, or services that I have mentioned, other than Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.
Wednesday, July 04, 2012
Laminitis: Video Lecture on Metabolic Pathway for Hoof Blog Readers
Please allow sufficient time for this video to load.
Settle down...You needed to get out of the heat anyway. Take an hour to catch up on the latest information about laminitis, with a special emphasis on insulin resistance and Equine Metabolic Syndrome.
What this is: a one-hour video Powerpoint lecture by Dr. Don Walsh on the latest research and horse management information related to laminitis, primarily via the metabolic pathway common in pleasure horses. A preliminary explanation of the septis-related form of laminitis is provided to differentiate between the two main forms of the disease.Thanks to EquiSearch.com and EQUUS magazine for hosting "Laminitis Lessons: A Webinar for Every Horse Owner" with The Animal Health Foundation's Don Walsh, DVM, and for making this video archive available to readers of The Hoof Blog.
Dr. Walsh |
It's not enough just to soak up the information shared in this webinar. It's not enough even to share this video and the information in it with horse owners or horsecare professionals. Please help by sharing information about the Animal Health Foundation, too and by supporting it with your donation--no matter how small--and encouraging others to do the same.
Without a doubt, horses who have laminitis--and horses who might be risk for laminitis--have benefited from the work of the Animal Health Foundation. Directly or indirectly, you have too. Please give back; the Animal Health Foundation will put your donation to work immediately.
Click on the "Donate Online Now" button to go to the Animal Health Foundation PayPal donation page and click on the "donate" button for PayPal. Donations are fully tax-deductible in the United States and may be submitted from any country, in any currency, via a number of credit cards, any time of the day or night. Thank you.
Donation checks may be sent to:
Animal Health Foundation 3615 Bassett Rd. Pacific, MO 63069
Photo of Dr. Walsh by Julie Plaster. Thanks!
© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is a between-issues news service for subscribers to Hoofcare and Lameness Journal. Please, no use without permission. You only need to ask. This blog may be read online at the blog page, checked via RSS feed, or received via a digest-type email (requires signup in box at top right of blog page). To subscribe to Hoofcare and Lameness (the journal), please visit the main site, www.hoofcare.com, where many educational products and media related to equine lameness and hoof science can be found. Questions or problems with this blog? Send email to blog@hoofcare.com.
Follow Hoofcare + Lameness on Twitter: @HoofcareJournal
Read this blog's headlines on the Hoofcare + Lameness Facebook Page
Disclosure of Material Connection: I have not received any direct compensation for writing this post. I have no material connection to the brands, products, or services that I have mentioned, other than Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.
Friday, June 29, 2012
Equine Laminitis Update: Belknap's Summary of Basic Facts
The recent--and some would say long overdue--expansion in laminitis research has spawned a generation of geeks who can speak the lingo and conject about the future. Their ideas are exciting--but what do we really know about laminitis, and how much more do we know that a year ago, or ten years ago?
Is it possible to find a cure for something you don't understand?
Dr. James Belknap, a leading laminitis researcher, recently wrote this succinct summary of what laminitis is, based on the few facts he and his researcher allies know to be the foundation of the disease.
It's not far off to say that what he describes here is the laminitis base camp. Research expeditions head out from here. Sherpas lead the way, but it is one step at a time and sometimes bad weather forces an expedition back to the base just when the summit is in sight. Everyone wants to stand at the summit, on top of the world. Getting there has not been easy, but here's what the tents at base camp are built upon.
Laminitis is not a disease of the foot as much as a disease of the horse--yet the foot has a delicate structure--what Dr. Belknap calls "target tissue"--that is incredibly sensitive to changes from the many triggers. And the target tissue gets bullseyed more often than we'd like.
From Dr. Belknap:
Equine laminitis can be a devastating result of many different disease processes in the horse, including, most commonly, sepsis and endocrinopathies. The two primary types of endocrinopathic laminitis are equine metabolic syndrome (seen most often in the obese horse), and Cushing’s syndrome in older horses (characterized by high levels of circulating steroids produced by a pituitary tumor). Interestingly, the “target” tissue in the horse for sepsis, equine metabolic syndrome, and Cushing’s syndrome is the digital laminae.Most likely the main reason the digital laminae are the primary target is because no other soft tissue structure in species injury/dysfunction will result in the entire collapse of the musculoskeletal system of the animal. The laminar basal epithelial cells are exposed to incredible forces (supporting the entire weight of the horse).
Dr. James Belknap is a leading researcher in the pathophysiology of laminitis. He is a professor at The Ohio State University College of Veterinary Medicine's Galbreath Equine Center. |
1. Laminitis related to septic conditions
Septic conditions in the horse that can lead to laminitis include gastrointestinal disease (surgical lesions, diarrhea/enteritis from infectious agents, or carbohydrate overload), retained placenta in the post-foaling broodmare leading to a uterine infection, pleuropneumonia, and any other infection in which enough tissue is compromised to result in systemic effects.In most of these cases, toxins absorbed from Gram-negative bacteria are thought to be responsible for the systemic problems such as laminitis. However, bacterial infections from other types of organisms can also result in laminitis. Most progress has been made in studying sepsis-related laminitis, as most experimental models for laminitis mimic this condition.
Systemic inflammation leading to inflammatory injury to the laminar tissue has been reported in sepsis-related laminitis in horses. In the laminae, this injury is characterized by adhesion and migration of circulating white blood cells out of the blood vessels into the laminar tissue. This is accompanied by massive increases in expression of inflammatory proteins such as cytokines (a 10-fold to > 2,000 fold increase in expression) and cyclooxygenase-2 (COX -2, the enzyme which is targeted by non-steroidal antiinflammatory drugs such as phenylbutazone or flunixin).
2. Laminitis related to Equine Metabolic Syndrome and Equine Cushing Syndrome
These events most likely cause injury to the laminar basal epithelial cells, leading to disruption of their critical cellular events, including adhesion to the underlying matrix. The matrix itself may also be injured by the release of matrix-degrading enzymes by leukocytes, epithelial cells, and other cell types in the laminae.Equine metabolic syndrome (EMS), which includes pasture-associated laminitis, is now the most common type of laminitis reported by veterinarians. Although the animals affected are commonly obese, animals in “show shape” that are not overtly obese also succumb to EMS-related laminitis.
A consistent factor in the horse or pony with EMS is insulin resistance, with the animals usually exhibiting increased circulating insulin concentrations. It has been suspected that laminar injury in EMS was from an inflammatory event as discovered in sepsis-related laminitis. However, recently presented data indicate that the high circulating insulin concentration itself can induce laminitis, with limited evidence of inflammation in the laminae.
The other type of endocrinopathic laminitis, Equine Cushing Syndrome (ECS), may have a pathophysiologic mechanism similar to that of EMS, as ECS horses similarly have high levels of circulating insulin. However, it is possible that the glucocorticoids (GCs) may be playing a role in disruption of the cell biology of the laminar keratinocytes in ECS.
3. Laminitis related to weightbearing (“supporting limb laminitis”)
The pathophysiology of supporting limb laminitis, the type suffered by Barbaro, is the type of laminitis about which we presently have the least knowledge. With this type, excessive weight bearing (usually due to a painful injury on the opposite limb) results in laminar failure. The recent interest supporting limb laminitis has resulted in several studies being funded by equine foundations.Hopefully, these studies will further elucidate the pathologic mechanisms (and thus therapeutic targets) for this equally devastating form of laminitis. Thus, laminitis is likely the end product of a diverse array of disease processes that lead to disruption and failure of a highly evolved cell type that is exquisitely sensitive to injury—the laminar basal epithelial cell.
James Belknap, DVM, PhD, DACVS is Professor of Veterinary Clinical Sciences from The Ohio State University Galbreath Equine Center and a leading researcher in the pathophysiology of laminitis. He shared this succinct summary of the current knowledge based on the types of laminitis via the Equine Disease Quarterly of the University of Kentucky’s Gluck Equine Research Center.
Easy online ordering and immediate shipping of our award-winning anatomy poster |
© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is a between-issues news service for subscribers to Hoofcare and Lameness Journal. Please, no use without permission. You only need to ask. This blog may be read online at the blog page, checked via RSS feed, or received via a digest-type email (requires signup in box at top right of blog page). To subscribe to Hoofcare and Lameness (the journal), please visit the main site, www.hoofcare.com, where many educational products and media related to equine lameness and hoof science can be found. Questions or problems with this blog? Send email to blog@hoofcare.com.
Follow Hoofcare + Lameness on Twitter: @HoofcareJournal
Read this blog's headlines on the Hoofcare + Lameness Facebook Page
Disclosure of Material Connection: I have not received any direct compensation for writing this post. I have no material connection to the brands, products, or services that I have mentioned, other than Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.
Tuesday, April 03, 2012
Grass Laminitis: What You Don’t Know Can Hurt You (and Your Horse) and Surprise the Researchers
New ad promo and publicity from Boehringer-Ingelheim Vetmedica perhaps oversimplifies grass laminitis. But it might get the attention of horse owners. |
Thursday, November 03, 2011
Prascend® PPID (Equine Cushings Disease) Treatment Approved by FDA for US Horses
The following press release is not an ad, it is published here as a "heads up". Anyone involved in the world of Hoofcare + Lameness is going to hear about this. Farriers and veterinarians will be asked questions by horseowners about this medication, and you need to know about how pergolide has evolved into Prascend®.
Prascend has been available in the United Kingdom for a few months, and Boehringer-Ingelheim Vetmedica has launched an awareness campaign there to urge horse owners to have their horses tested for PPID. I don't know yet what B-I has planned in the USA, but I feel confident in saying that "this is news".
In 2007, this blog reported that a potential crisis loomed for horseowners who were treating the symptoms of their horses' PPID condition with Permax (pergolide). (See links at end of this blog post.) The medication was taken from the market temporarily because of problems with human prescriptions. Before long, it became available again in the compounded form, which many horse owners ordered directly and in different forms.
Compounding pharmacies have been at the center of a controversy in the veterinary industry. At this time, it is too early to give a reliable answer whether compounded (and less expensive) pergolide will remain an option for horseowners as pill-only Prascend enters the marketplace. Ideally, horseowners will have safe and multiple alternatives to keep their horses comfortable.
Much more information will be available at or following the AAEP Convention in San Antonio later this month.
Prascend has been available in the United Kingdom for a few months, and Boehringer-Ingelheim Vetmedica has launched an awareness campaign there to urge horse owners to have their horses tested for PPID. I don't know yet what B-I has planned in the USA, but I feel confident in saying that "this is news".
In 2007, this blog reported that a potential crisis loomed for horseowners who were treating the symptoms of their horses' PPID condition with Permax (pergolide). (See links at end of this blog post.) The medication was taken from the market temporarily because of problems with human prescriptions. Before long, it became available again in the compounded form, which many horse owners ordered directly and in different forms.
Compounding pharmacies have been at the center of a controversy in the veterinary industry. At this time, it is too early to give a reliable answer whether compounded (and less expensive) pergolide will remain an option for horseowners as pill-only Prascend enters the marketplace. Ideally, horseowners will have safe and multiple alternatives to keep their horses comfortable.
Much more information will be available at or following the AAEP Convention in San Antonio later this month.
Boehringer Ingelheim’s Prascend® Approved for PPID in Horses
Product is the first and only FDA-approved treatment for the management of PPID.
PRASCEND is the first and only FDA-approved product for the management of PPID in horses. (1) Administered in tablet form, treatment with PRASCEND can improve the quality of life for PPID-affected horses by managing clinical signs and decreasing the risk of complications of the disease, including those that have the potential to be life-threatening.
It is estimated that one in seven horses over the age of 15 has PPID (2) and horses as young as seven years of age have been diagnosed with the disease (3). In addition, up to 70 percent of clinical laminitis cases also may be affected with underlying PPID4. The most common clinical signs of advanced-stage PPID that occur in horses are hirsutism (hypertrichosis) or an abnormal amount of hair growth, abnormal sweating, weight loss, muscle wasting, abnormal fat distribution, lethargy, laminitis, polyuria/polydipsia and chronic/recurrent infections.
“Unfortunately, PPID is not a curable disease,” says Dr. John Tuttle, BIVI equine technical services veterinarian. “However, PRASCEND does offer a safe and efficacious treatment option to veterinarians and horse owners that can help reduce the clinical signs of the disease and effectively improve the quality of life of infected horses.”
While PPID is typically considered a late-stage-of-life disease in the horse, Tuttle adds that with horse owner vigilance and regular veterinary care, the disease may be detected earlier.
“Because the early symptoms of PPID may be difficult to recognize, some horses with PPID may go undiagnosed until the disease becomes more advanced,” says Tuttle. “Through regular veterinary wellness exams, oftentimes the disease can be caught earlier. By beginning treatment in the earlier stages of the disease, we are able to reduce the risk of some of the potential complications associated with PPID, such as laminitis, recurring infections, dental disease and other potential issues of uncontrolled PPID.”
Not only can PRASCEND aid in the management of clinical signs of disease, the FDA approval also assures the product has been thoroughly evaluated for safety and efficacy. In addition, PRASCEND has met the standards set forth by the FDA in regard to production to preserve its identity, strength, quality, purity and consistency from batch to batch, and the product has demonstrated stability and effectiveness over time through a variety of environmental conditions.
“We are excited to offer a treatment option for horses suffering from PPID,” says Tuttle. “We encourage horse owners to continue to work with their veterinarians to find the best treatment for their horse and are confident that PRASCEND can help make a difference in the lives of horses suffering from this disease.”
800-325-9167.
(Hoof Blog note: A web address should be available soon.)
Reference:
- PRASCEND® (pergolide mesylate) [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.
- McGowan TW, Hodgson DR, McGowan CM. The prevalence of equine Cushing’s syndrome in aged horses. In: Proceedings from the 25th American College of Veterinary Internal Medicine Forum; June 6–9, 2007; Seattle, WA. Abstract 603.
- Schott HC. Pars pituitary intermedia dysfunction: challenges of diagnosis and treatment. In: Proceedings from the 52nd American Association of Equine Practitioners Annual Convention; December 2–6, 2006; San Antonio, TX.
- Donaldson MT. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc. 2004;224(7):1123–1127.
TO LEARN MORE
AAEP Statement on FDA Withdrawal of Pergolide for Human Use: Will It Still Be Available for Horses?
Pergolide Cleared for Equine Veterinary Use by FDA
Laminitis Research: Australian Breakthrough on Insulin Function in Equine Foot
Too Fat? Too Thin? British Court Faces Conflict Over "Abused" Horse with Cushings Disease
Cornell Laminitis Research Beneficiary of Arabian Horse Foundation Grant to Study Genetic Markers in Equine Metabolic Syndrome and Cushings Disease
Equine Pituitary Dysfunction Test Choices Analyzed by New Bolton Center's Jill Beech VMD
Three Chimneys Farm Works to Help Slew 'o Gold Keep His Cool
© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is a between-issues news service for subscribers to Hoofcare and Lameness Journal. Please, no use without permission. You only need to ask. This blog may be read online at the blog page, checked via RSS feed, or received via a digest-type email (requires signup in box at top right of blog page). To subscribe to Hoofcare and Lameness (the journal), please visit the main site, www.hoofcare.com, where many educational products and media related to equine lameness and hoof science can be found. Questions or problems with this blog? Send email to blog@hoofcare.com.
Follow Hoofcare + Lameness on Twitter: @HoofcareJournal
Read this blog's headlines on Facebook
Disclosure of Material Connection: I have not received any direct compensation for writing this post. I have no material connection to the brands, products, or services that I have mentioned, other than Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.
Friday, July 01, 2011
Laminitis Research: Australian Breakthrough on Insulin Function in Equine Foot
(Text published as provided)
Researchers funded by the US-based Animal Health Foundation announced June 15, 2011, that they have made a major breakthrough in understanding how the insulin form of laminitis occurs.
Drs. Melody de Laat and Chris Pollitt of the Australian Equine Laminitis Research Unit at the University of Queensland have discovered that receptors designed to receive insulin-like growth factor 1 (IGF-1) may be binding to insulin instead if horses have high levels of insulin.
This groundbreaking discovery may enable scientists to develop strategies to try to block IGF-1 receptors from receiving insulin and prevent the disease from occurring.
The receptor also has been shown to be responsible for the metastatis of malignant tumors in humans, and drugs currently are being developed to block the receptor. These drugs may be of use in trying to treat horses that are prone to laminitis from developing high levels of insulin.
Insulin is important in regulating the blood glucose within animals, but horses that have Equine Metabolic Syndrome and Cushing’s disease often have very high levels of insulin.
Pollitt and his team, funded by AHF since 1995, previously showed that high insulin is one of the major pathways that causes laminitis, but, to this point, they had not understood how.
The equine foot is very dependent on glucose for metabolism, but it is not dependent on insulin to deliver that glucose. Horses have a large number of IGF-1 receptors in their feet, but no insulin receptors. Pollitt’s team now theorizes that these IGF-1 receptors are being stimulated by insulin that mimics insulin-like growth factor 1 and is binding to these receptors.
When this happens, the laminar epitheleal cells start to proliferate. Normally these cells in the middle of the foot don’t multiply. The cells are made at the coronary band and migrate all the way down to the sole without multiplying.
This type of proliferation causes the laminae to stretch and lengthen and the weight of the horse to ruin the bond between the external hoof wall and the bone. The bone changes position, and laminitis occurs.
“We’re starting to understand the pathway of how insulin really causes laminitis,” said Dr. Don Walsh, president of the Animal Health Foundation.
© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is a between-issues news service for subscribers to Hoofcare and Lameness Journal. Please, no use without permission. You only need to ask. This blog may be read online at the blog page, checked via RSS feed, or received via a digest-type email (requires signup in box at top right of blog page). To subscribe to Hoofcare and Lameness (the journal), please visit the main site, www.hoofcare.com, where many educational products and media related to equine lameness and hoof science can be found. Questions or problems with this blog? Send email to blog@hoofcare.com.
Researchers funded by the US-based Animal Health Foundation announced June 15, 2011, that they have made a major breakthrough in understanding how the insulin form of laminitis occurs.
Drs. Melody de Laat and Chris Pollitt of the Australian Equine Laminitis Research Unit at the University of Queensland have discovered that receptors designed to receive insulin-like growth factor 1 (IGF-1) may be binding to insulin instead if horses have high levels of insulin.
This groundbreaking discovery may enable scientists to develop strategies to try to block IGF-1 receptors from receiving insulin and prevent the disease from occurring.
The receptor also has been shown to be responsible for the metastatis of malignant tumors in humans, and drugs currently are being developed to block the receptor. These drugs may be of use in trying to treat horses that are prone to laminitis from developing high levels of insulin.
Insulin is important in regulating the blood glucose within animals, but horses that have Equine Metabolic Syndrome and Cushing’s disease often have very high levels of insulin.
Pollitt and his team, funded by AHF since 1995, previously showed that high insulin is one of the major pathways that causes laminitis, but, to this point, they had not understood how.
The equine foot is very dependent on glucose for metabolism, but it is not dependent on insulin to deliver that glucose. Horses have a large number of IGF-1 receptors in their feet, but no insulin receptors. Pollitt’s team now theorizes that these IGF-1 receptors are being stimulated by insulin that mimics insulin-like growth factor 1 and is binding to these receptors.
When this happens, the laminar epitheleal cells start to proliferate. Normally these cells in the middle of the foot don’t multiply. The cells are made at the coronary band and migrate all the way down to the sole without multiplying.
This type of proliferation causes the laminae to stretch and lengthen and the weight of the horse to ruin the bond between the external hoof wall and the bone. The bone changes position, and laminitis occurs.
“We’re starting to understand the pathway of how insulin really causes laminitis,” said Dr. Don Walsh, president of the Animal Health Foundation.
Journey from coffin bone to periople in a colorful detailed super-microscopic image! Click to order! |
© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is a between-issues news service for subscribers to Hoofcare and Lameness Journal. Please, no use without permission. You only need to ask. This blog may be read online at the blog page, checked via RSS feed, or received via a digest-type email (requires signup in box at top right of blog page). To subscribe to Hoofcare and Lameness (the journal), please visit the main site, www.hoofcare.com, where many educational products and media related to equine lameness and hoof science can be found. Questions or problems with this blog? Send email to blog@hoofcare.com.
Read this blog's headlines when you "like" the Hoofcare + Lameness Facebook Page
Disclosure of Material Connection: I have not received any direct compensation for writing this post. I have no material connection to the brands, products, or services that I have mentioned, other than Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.
Subscribe to:
Posts (Atom)